As trading begins, the stock price of Microbot Medical Inc. (NASDAQ: MBOT) is continuing to rise. MBOT shares have increased 15.29% to $2.94 as of the most recent pre-market check, building on the previous session’s 17.51% rise that ended at $2.55. This increasing trend comes after important late-breaking study evidence was recently accepted, which boosted investor confidence.
Results of the Liberty Trial will be presented at the SIR Annual Meeting.
A late-breaking abstract from Microbot Medical’s ACCESS-PVI study was accepted for presentation at the next Society of Interventional Radiology (SIR) annual conference, the company reported last week. The trial’s results will be presented on a podium during the conference, which is scheduled to take place in Nashville, Tennessee, from March 29 to April 2, 2025.
The performance and safety of LIBERTY, a remote-controlled, single-use robotic device intended for peripheral vascular treatments, are being evaluated in the ACCESS-PVI trial, a prospective, multicenter, single-arm research. The study is called “Remote-controlled endovascular navigation using a small, disposable robotic device.” Results of the ACCESS-PVI trial,” will be presented by Dr. François Cornelis, MD, PhD, FCIRSE, of Memorial Sloan Kettering Cancer Center’s Department of Radiology.
The acceptance of this late-breaking abstract marks a crucial milestone for Microbot Medical, as it provides an opportunity for Principal Investigators to showcase the LIBERTY system to a highly relevant audience—potential users within the interventional radiology community.
Increasing Operations Prior to the Commercial Launch of LIBERTY
Microbot Medical has named Ms. Michal Ahuvia Director of Operations in anticipation of LIBERTY’s expected commercial launch in the second quarter of 2025. Ms. Ahuvia will be in charge of increasing output and improving operational efficiency, reporting to Simon Sharon, the company’s general manager and chief technology officer.
With more than 20 years of operations expertise in areas such as supply chain management, logistics, material planning, and process transformation, Ms. Ahuvia is anticipated to be essential in carrying out Microbot Medical’s business plan. Her experience will be crucial in streamlining production procedures as the business expands LIBERTY’s output in order to successfully satisfy consumer demand.